This report provides exclusive insights into the COVID-19 impact on the Erythropoietin Drugs Market. The detailed analysis provides information about the impact of the outbreak on the demand and supply conditions, trends and forecasts of the Erythropoietin Drugs Market. Moreover, the impact analysis covers the study of the COVID-19 on the supply chain of Erythropoietin Drugs Market. The sectoral impact shall provide insights into both short term and long term effects of the pandemic on the related and support industries.
A recent report published by Infinium Global Research on
erythropoietin drugs market provides in-depth analysis of segments and sub-segments
in the global as well as regional erythropoietin drugs market. The study also
highlights the impact of drivers, restraints, and macro indicators on the
global and regional erythropoietin drugs market over the short term as well as
long term. The report is a comprehensive presentation of trends, forecast and
dollar values of the global erythropoietin drugs market. According to the report,
the global erythropoietin drugs market is projected to grow at a CAGR of 10.2%
over the forecast period of 2019-2025.
Erythropoietin (EPO) was the first recombinant deoxyribonucleic
acid (DNA) drug to arrive common medical use in the U.S. Medicare is by far the
largest payer for EPO because Medicare covers about 93 percent of dialysis
patients. As a result of Medicare coverage and payment regulations
significantly influence the financial environment physicians and dialysis
facilities face in attempting to balance the best care for patients with the
fiscal reality. Hemoglobin levels and the dose of erythropoiesis-stimulating
agents (ESAs) have increased in hemodialysis patients in the United States. It
is a glycoprotein hormone that controls erythropoiesis or production of red
blood cells. They are used in the treatment of different diseases like cancer and
chronic renal diseases.
An increasing number of patients suffering from anemic condition
induced due to cancer, HIV and End-Stage Renal Disease (ESRD) treatment is the
major driving factor for the erythropoietin drugs market. Furthermore, factors
such as the presence of large patient populations, patent expiration of
biologics and an increase in the availability of biosimilars are other driving
factors for the market growth. The use of EPO is held to increase oxygen
absorption, reduce fatigue and improve endurance by increasing the rate of red
cell production. It is also held that EPO increases the metabolism and the
healing process of muscles because the extra red cells carry more oxygen and
nutrients. Rising incidence of chronic kidney disease (CKD), cancer and HIV
fueling the growth of the market. However, the high cost of EPO drugs is the
major restraint factor for the erythropoietin drugs market. Moreover, patent
expiration of major biologics during the coming years are anticipated to
provide wide growth opportunities to the market players.
Geographically, North America dominates the global erythropoietin
drugs market owing to continuously increasing cancer population and patient
suffering from renal diseases in this region. Europe is the second-largest
market for erythropoietin drugs followed by Asia-Pacific.
The report on global erythropoietin drugs market covers segments
such as drug class, product, and applications. On the basis of drug class, the
sub-markets include biologics, and biosimilars. On the basis of product, the
sub-markets include epoetin-alfa, epoetin-beta, darbepoetin-alfa, and other
products. On the basis of applications, the sub-markets include cancer,
hematology, renal diseases, and neurology.
The report provides profiles of the companies in the market such
as Hospira Inc., Johnson & Johnson, Amgen Inc., Roche Holding AG, LG Life
Sciences Ltd., Biocon Limited, Celltrion, Inc., Intas Pharmaceuticals, Teva
Pharmaceutical Industries Ltd., Ranbaxy Laboratories Ltd., and other companies.
The report provides deep insights into the demand forecasts,
market trends, and micro and macro indicators. In addition, this report
provides insights into the factors that are driving and restraining the growth
in this market. Moreover, The IGR-Growth Matrix analysis given in the report
brings an insight into the investment areas that existing or new market players
can consider. The report provides insights into the market using analytical
tools such as Porter's five forces analysis and DRO analysis of erythropoietin
drugs market. Moreover, the study highlights current market trends and provides
forecast from 2019-2025. We also have highlighted future trends in the market
that will affect the demand during the forecast period. Moreover, the
competitive analysis given in each regional market brings an insight into the
market share of the leading players.